SV

Street Verdict

Analyst Scorecard

BPLPHARMA.BO · BSE

Bharat Parenterals Limited

₹1,538

+2.25% (+₹33.85)

Prev. close

₹1,504.15

Volume

32

As of

BSE · may be slightly delayed · 09:46 IST

Price history

₹1,349.45+₹109.35 (+8.82%) · 3M
13 May 2026 → 14 Aug 2026
₹1,530.2₹1,214.913 May05 Jun01 Jul23 Jul14 Aug
Daily closes · updates after each session

No analyst calls on this stock in the last 90 days yet.

Explore by date range →

Analyst opinions

No analyst calls on Bharat Parenterals Limited in the last 90 days.

Fundamentals

About Bharat Parenterals Limited

Bharat Parenterals Limited engages in the research, development, manufacturing, marketing, sourcing, and distribution of pharmaceutical products in India and internationally. The company provides antibiotics, cardiovascular and central nervous system, antifungal, antimalarial, gastrointestinal tract/alimentary systems, analgesics, anaesthetics, quinolones, erectile dysfunction medicines, nutritional supplements, steroids and hormones, and other drugs. It also engages in manufacturing general products in capsules, tablets, ointment and creams, injections, oral liquids, and powder sachets forms; and beta lactum and cephalosporin products in capsules, tablets, dry syrup, and powder for injection forms. In addition, it offers research, development and manufacture of pharmaceutical formula ons, including sterile injectable products, oral liquid formula ons, prefilled syringes, other specialty, and eye drops. Bharat Parenterals Limited was incorporated in 1992 and is based in Vadodara, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Bharatkumar Rameshchandra Desai

Headquarters

Vadodara

Employees

404

Key stats

Market cap

₹1,033.79 Cr

Dividend yield

0.07%

EPS (TTM)

₹-22.41

Beta (1Y · daily vs NIFTY 50)

0.78

Beta (5Y · monthly vs NIFTY 50)

1.61

Shares float

14.50 L

EPS · quarter ended Jun 2026

₹1.46

Financial Performance

01 · Financials

-200 Cr0 Cr200 Cr400 Cr₹-20%0%20%40%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDARevenue growth YoY

Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.2% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.

02 · Earnings Per Share (EPS)

-2002040₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

00111₹0%10%20%30%40%25 Sept 2325 Jun 2419 Sept 2511 Sept 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: Yahoo (no NSE corporate-actions ledger for this listing).

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

-50%0%50%100%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr250 Cr500 Cr750 Cr₹0×0.2×0.4×0.6×0.8×FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr250 Cr500 Cr750 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

-200 Cr-100 Cr0 Cr100 Cr200 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹204.64 Cr₹212.01 Cr₹217.56 Cr₹257.05 Cr₹335.48 Cr₹343.05 Cr
EBITDA₹33.92 Cr₹35.43 Cr₹31.62 Cr₹30.92 Cr₹13.29 Cr₹24.29 Cr
₹20.31 Cr₹20.81 Cr₹16.44 Cr₹14.52 Cr₹-12.63 Cr₹-8.19 Cr
Diluted EPS₹35.59₹36.67₹28.4₹24.94₹-19.26₹-11.88

Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
——₹350.34 Cr₹504.04 Cr₹648.53 Cr₹613.30 Cr
——₹49.74 Cr₹157.58 Cr₹180.20 Cr₹146.11 Cr
Stockholders' equity——₹182.80 Cr₹197.27 Cr₹330.67 Cr₹322.23 Cr

Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
——₹21.66 Cr₹-4.71 Cr₹-27.25 Cr₹38.36 Cr
Investing cash flow——₹-77.82 Cr₹-104.78 Cr₹-137.39 Cr₹9.32 Cr
——₹60.60 Cr₹110.43 Cr₹156.37 Cr₹-47.05 Cr
Capital expenditure——₹-91.60 Cr₹-104.30 Cr₹-29.08 Cr₹-39.93 Cr
End cash position——₹7.84 Cr₹8.78 Cr₹44.28 L₹1.20 Cr

Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.48 L Cr₹1,837.337.05.3613.7%0.06+11.9%+11.4%
Divi's Laboratories Limited₹2.47 L Cr₹9,37583.314.7715.3%0.00+12.3%+53.4%
Torrent Pharmaceuticals Limited₹1.83 L Cr₹4,87576.921.8225.8%1.79+21.5%+37.4%
Apollo Hospitals Enterprise Limited₹1.26 L Cr₹8,944.560.413.3020.5%0.90+15.7%+13.9%
Lenskart Solutions Limited₹1.18 L Cr₹707.2179.913.485.6%0.35+35.4%—
Zydus Lifesciences Limited₹1.13 L Cr₹1,16025.34.1818.6%0.46+18.4%+10.7%
Cipla Limited₹1.10 L Cr₹1,376.332.53.1911.3%0.02+2.1%-11.8%
Laurus Labs Limited₹1.05 L Cr₹1,95496.419.8616.8%0.48+22.0%+111.6%
Max Healthcare Institute Limited₹1.01 L Cr₹1,049.369.89.3913.4%0.32+19.0%-10.6%
Dr. Reddy's Laboratories Limited₹97,876.16 Cr₹1,18529.62.6011.4%0.21+3.2%-10.4%
Manipal Health Enterprises Limited₹97,364.22 Cr₹738.95146.611.567.8%1.53+18.0%—
Bharat Parenterals Limited₹1,066.15 Cr₹1,349.45—3.31-2.5%0.45+2.3%+2.2%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Annual reports

Show all 15

Concall transcripts

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

BPLPHARMA.BO

Bharat Parenterals doubles Savli facility capex to Rs. 300 crore as it targets global biologics CDMO market

Indian Pharma Post · 1 month ago